CheckMate 743 — Nivolumab Plus Ipilimumab Versus Chemotherapy for First-Line Unresectable Malignant Pleural Mesothelioma

Phase 3 · 2021 · Mesothelioma

Design

Randomized nivolumab plus ipilimumab vs platinum plus pemetrexed chemotherapy.

Population

Untreated unresectable malignant pleural mesothelioma, epithelioid and non-epithelioid histology.

Primary Endpoint

overall survival (OS)

Key Result

OS 18.1 vs 14.1 mo (HR 0.74); benefit most pronounced in non-epithelioid histology, which responds poorly to chemotherapy.

Guideline Impact

NCCN category 1 first-line nivolumab + ipilimumab for unresectable pleural mesothelioma